107 related articles for article (PubMed ID: 6384571)
1. [Schizophrenia and neurotransmitters].
Nagatsu T; Fujita K; Kawai K; Shinpo K; Shinzato M
Nihon Rinsho; 1984 Apr; 42(4):891-901. PubMed ID: 6384571
[No Abstract] [Full Text] [Related]
2. [Current biochemical conceptions of mental disorders. I. Biogenic amines in the pathogenesis of schizophrenia].
Anokhina IP; Gamaleia NB
Zh Nevropatol Psikhiatr Im S S Korsakova; 1979; 79(8):1096-1105. PubMed ID: 384732
[No Abstract] [Full Text] [Related]
3. Neuropsychopharmacology of monoamines and their regulatory enzymes.
Lipton MA
Adv Biochem Psychopharmacol; 1974; 12(0):443-54. PubMed ID: 4153941
[No Abstract] [Full Text] [Related]
4. Norepinephrine reward pathways: role of self-stimulation, memory consolidation, and schizophrenia.
Stein L
Nebr Symp Motiv; 1975; 22():113-59. PubMed ID: 1688
[No Abstract] [Full Text] [Related]
5. [Biochemistry of schizophrenia and mechanism of action of neuroleptics].
Loo H; Cuche H; Sechter D
Sem Hop; 1982 Dec; 58(44):2565-72. PubMed ID: 6130604
[TBL] [Abstract][Full Text] [Related]
6. Semidehydroascorbate as a product of the enzymic conversion of dopamine to norepinephrine. Coupling of semidehydroascorbate reductase to dopamine-beta-hydroxylase.
Diliberto EJ; Allen PL
Mol Pharmacol; 1980 May; 17(3):421-6. PubMed ID: 7393218
[No Abstract] [Full Text] [Related]
7. Toward hypotheses for a biochemical component in the vulnerability to schizophrenia.
Kety SS
Semin Psychiatry; 1972 Aug; 4(3):233-8. PubMed ID: 4155537
[No Abstract] [Full Text] [Related]
8. [Effects of antibodies to dopamine-beta-monooxygenase on the level of catecholamines in the brain].
Pogosian AS; Boiadzhian AS; Karagezian KG; Aĭvazian VA; Movsesian AV
Biull Eksp Biol Med; 1991 Aug; 112(8):133-4. PubMed ID: 1786369
[No Abstract] [Full Text] [Related]
9. Dopamine-beta-hydroxylase, monoamine oxidase, and schizophrenia.
DeLisi LE; Wise CD; Potkin SG; Zalcman S; Phelps BH; Lovenberg W; Wyatt RJ
Biol Psychiatry; 1980 Dec; 15(6):895-907. PubMed ID: 7459411
[TBL] [Abstract][Full Text] [Related]
10. Possible etiology of schizophrenia: progressive damage to the noradrenergic reward system by endogenous 6-hydroxydopamine.
Stein L; Wise CD
Res Publ Assoc Res Nerv Ment Dis; 1972; 50():298-314. PubMed ID: 5071537
[No Abstract] [Full Text] [Related]
11. Quantitation of 3,4-dihydroxyphenylacetaldehyde and 3, 4-dihydroxyphenylglycolaldehyde, the monoamine oxidase metabolites of dopamine and noradrenaline, in human tissues by microcolumn high-performance liquid chromatography.
Burke WJ; Chung HD; Li SW
Anal Biochem; 1999 Aug; 273(1):111-6. PubMed ID: 10452806
[TBL] [Abstract][Full Text] [Related]
12. Biochemical aspects of schizophrenia.
Lewis ME
Essays Neurochem Neuropharmacol; 1980; 4():1-67. PubMed ID: 6104597
[No Abstract] [Full Text] [Related]
13. Neurotransmitter-related enzymes in the major psychiatric disorders: II. MAO and DBH in schizophrenia.
Wyatt RJ; Murphy DL
Res Publ Assoc Res Nerv Ment Dis; 1975; 54():289-97. PubMed ID: 769116
[No Abstract] [Full Text] [Related]
14. Prolactin levels in schizophrenia: relation to platelet monoamine oxidase, plasma amine oxidase, plasma dopamine-beta-hydroxylase, and erythrocyte catechol-O-methyltransferase activity.
Baron M; Levitt M; Asnis L; Fein M
Biol Psychiatry; 1983 May; 18(5):579-82. PubMed ID: 6860731
[No Abstract] [Full Text] [Related]
15. Behavioral and neurobiological changes in C57BL/6 mice exposed to cuprizone.
Xu H; Yang HJ; Zhang Y; Clough R; Browning R; Li XM
Behav Neurosci; 2009 Apr; 123(2):418-29. PubMed ID: 19331464
[TBL] [Abstract][Full Text] [Related]
16. [Inadequacy of the monoamine oxidase system--the probable pathogenetic factor in schizophrenia (review)].
Kolpakov VG
Zh Nevropatol Psikhiatr Im S S Korsakova; 1974; 74(8):1254-63. PubMed ID: 4278558
[No Abstract] [Full Text] [Related]
17. Effect of amphetamine on brain catecholamines, brain beta-endorphin, serum prolactin, catechol-O-methyltransferase and monoamine oxidase of various organs in the rat.
Agarwal DP; Hoo JJ; Tjaden A; Nishigaki I; Beckermann WJ; Pahnke V; Goedde HW
Arzneimittelforschung; 1985; 35(11):1639-42. PubMed ID: 2936351
[TBL] [Abstract][Full Text] [Related]
18. [Determination of dopamine-beta-hydroxylase (DBH) and monoamine oxidase (MAO) activities in platelets and plasma in schizophrenic, maniac-depressive and neurotic patients].
Xavier Vieira R; Azevedo M; Polónio P; Manso C
Acta Med Port; 1986; 7(1):45-8. PubMed ID: 3728081
[No Abstract] [Full Text] [Related]
19. [Neuroleptics, monoamine oxidase inhibitors and dopamine beta hydroxylase inhibitors: their actions and interactions].
Vetulani J
Postepy Hig Med Dosw; 1973; 27(6):725-80. PubMed ID: 4589208
[No Abstract] [Full Text] [Related]
20. [Findings of biochemical research on schizophrenia (author's transl)].
Ackenheil M; Hippius H; Matussek N
Nervenarzt; 1978 Nov; 49(11):634-49. PubMed ID: 31575
[No Abstract] [Full Text] [Related]
[Next] [New Search]
